← Eichor
Condition: Selected Types Of Solid Tumor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Selected Types Of Solid Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected
Phase 1/Phase 2 · 6 location(s) · Everest Medicines (Beijing) Co., Ltd. · NCT07095868A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (
EARLY_Phase 1 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT05141474A Study of YL202 in Selected Patients With Advanced Solid Tumors
Phase 2 · 82 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06107686Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advance
Phase 1/Phase 2 · 4 location(s) · CJ Bioscience, Inc. · NCT05877430A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants Wit
Phase 1 · 47 location(s) · BeOne Medicines · NCT06427941A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 9 location(s) · Apollo Therapeutics Ltd · NCT06399757Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Phase 1 · 2 location(s) · Canadian Cancer Trials Group · NCT07297667A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants
Phase 1/Phase 2 · 9 location(s) · STORM Therapeutics LTD · NCT06975293Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or
Phase 1/Phase 2 · 1 location(s) · AP Biosciences Inc. · NCT05473156First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Se
Phase 1 · 3 location(s) · Molecure S.A. · NCT05759923A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Phase 1/Phase 2 · 41 location(s) · Alentis Therapeutics AG · NCT07169734A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 · 8 location(s) · ALX Oncology Inc. · NCT07085091Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 · 3 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT07517198A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07532902An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Phase 1 · 7 location(s) · FBD Biologics Limited · NCT06487624A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Select
Phase 1 · 2 location(s) · Kupando GmbH · NCT07600476LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT04665388A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Phase 1/Phase 2 · 41 location(s) · Alentis Therapeutics AG · NCT06747585TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Portage Biotech · NCT04969315Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07598955Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Phase 1 · 8 location(s) · Zai Lab (Shanghai) Co., Ltd. · NCT07374848A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Phase 1 · 9 location(s) · Avacta Life Sciences Ltd · NCT04969835
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.